Aligning Cancer Clinical Trials With Cancer Burden: Need for Greater Global Leadership, Resources, and Vision
Menée à partir de l'analyse des données de 694 essais cliniques de phase I à III ayant fait l'objet d'une publication entre 2014 et 2017, cette étude compare les caractéristiques des essais cliniques des pays à haut revenu avec celles des pays à revenu faible ou intermédiaire (sources de financement, nombre de patients inclus, taux de décès par type de cancer, ...)
Despite tremendous progress in cancer treatment and prevention made over the past few decades, the global cancer burden is estimated to exceed 29 million new diagnoses annually by 2040, along with more than 16 million cancer-related deaths. The worldwide rise of cancer burden will continue to disproportionately affect low- and middle-income countries (LMICs), where the proportion of global deaths is projected to increase from 65% in 2012 to 75% by 2030. Alignment between clinical trial resources, infrastructure, and research leadership with the known distribution of the global cancer burden has not been well studied.
JAMA Oncology , éditorial, 2020